Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta‐analysis of randomized clinical trials
Cancer Medicine · 2023
DOI: 10.1002/cam4.6564 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Cancer Medicine, 2023. Verfasst von Shoutao Dang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Head and Neck Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) showed antitumor activity for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, the results from different studies were controversial.
Methods
Online databases were searched for randomized clinical trials (RCTs) evaluating ICIs for R/M HNSCC. The characteristics of the studies and the results of overall survival (OS), progression‐free survival (PFS), objective response rate (ORR), treatment‐related adverse events (TRAEs) were extracted.
Results
A total of 4936 patients from eight studies were included. Anti‐PD1/PDL1 monotherapy significantly improved OS in total population (hazard ratio, HR, 0.87, 95% CI, 0.79–0.95, p = 0.003) and PD‐L1 high expression patients (HR, 0.71, 95% CI, 0.55–0.90, p = 0.006) with significant lower incidence of any grade TRAEs (odds ratio, OR, 0.16, 95% CI, 0.07–0.37, p < 0.00001) and Grades 3–5 TRAEs (OR, 0.18, 95% CI, 0.10–0.33, p < 0.0001) compared with standard of care (SOC); however, the pooled results of PFS and ORR were not significant different. PD1/PDL1 inhibitors plus CTLA4 inhibitors did not improve OS, PFS, ORR compared with SOC or ICIs monotherapy; however, the incidence of Grades 3–5 TRAEs was significant higher compared with ICIs monotherapy (OR, 1.80, 95% CI, 1.34–2.41, p = 0.0001).
Conclusions
Anti‐PD1/PDL1 monotherapy could improve OS for R/M HNSCC with significant lower incidence of TRAEs compared with SOC. PD1/PDL1 inhibitors plus CTLA4 inhibitors showed no more benefit compared with both SOC and ICIs monotherapy, but the incidence of Grades 3–5 TRAEs was significant higher compared with ICIs monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Shoutao Dang, Wei Li
Zitieren
APA
Dang, S., Zhang, S., Zhao, J., Li, X., & Li, W. (2023). Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta‐analysis of randomized clinical trials. Cancer Medicine. https://doi.org/10.1002/cam4.6564
Vancouver
Dang S, Zhang S, Zhao J, Li X, Li W. Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta‐analysis of randomized clinical trials. Cancer Medicine. 2023. doi:10.1002/cam4.6564
BibTeX
@article{Dang2023,
author = {Dang, Shoutao and Zhang, Shurong and Zhao, Jingyang and Li, Xinyu and Li, Wei},
title = {Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta‐analysis of randomized clinical trials},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6564}
}
EUVIMED